OPKO Health, Inc. (NASDAQ:OPK) Receives Consensus Recommendation of "Buy" from Analysts

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) has earned a consensus rating of "Buy" from the five analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $2.75.

Several equities research analysts have recently issued reports on OPK shares. Wall Street Zen cut OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. LADENBURG THALM/SH SH raised shares of OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. JPMorgan Chase & Co. began coverage on shares of OPKO Health in a research note on Friday, April 25th. They set a "neutral" rating for the company. Finally, Barrington Research reiterated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a report on Thursday, May 1st.

Institutional Investors Weigh In On OPKO Health

Several institutional investors have recently bought and sold shares of OPK. Oak Thistle LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at about $26,000. GM Advisory Group LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at $33,000. Cerity Partners LLC purchased a new stake in OPKO Health during the first quarter worth $36,000. Pallas Capital Advisors LLC acquired a new stake in OPKO Health during the first quarter valued at $43,000. Finally, Voleon Capital Management LP purchased a new stake in shares of OPKO Health during the 1st quarter worth about $45,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Stock Down 2.8%

NASDAQ:OPK traded down $0.04 during mid-day trading on Monday, hitting $1.24. 1,829,350 shares of the company's stock were exchanged, compared to its average volume of 3,907,747. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The company has a market cap of $980.32 million, a PE ratio of -4.94 and a beta of 1.19. OPKO Health has a one year low of $1.11 and a one year high of $2.04. The business has a fifty day moving average price of $1.34 and a 200 day moving average price of $1.47.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The company's revenue for the quarter was down 13.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.01) earnings per share. Equities analysts predict that OPKO Health will post -0.25 EPS for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.